One compound sometimes shows two
biological functions, becoming important aspect of recent
drug discovery. This study began with an attempt to confirm the previously reported molecular mechanism of the anti-human immunodeficiency virus (HIV)
heterocyclic compound BMMP [2-(benzothiazol-2-ylmethylthio)-4-methylpyrimidine], i.e., induction of abnormal uncoating of the viral core at the post-entry step. Our mechanistic study gave results consistent with this mechanism. We further attempted to find out the molecular target of
BMMP by a pulldown approach using previously synthesized biotinylated
BMMP (
Biotin-
BMMP) and successfully identified heterogenous nuclear
ribonucleoprotein M (
hnRNP M) as a
BMMP-
binding protein. This
protein was found not to be accountable for the anti-HIV activity of
BMMP. As
hnRNP M has been reported to promote
cancer metastasis, we tested this mechanism and found that
BMMP suppressed migration of the human lung
carcinoma cell line A549 stimulated with
transforming growth factor-β (TGF-β). Mechanistic study showed that
BMMP suppressed the expression of CD44
mRNA via the regulation of
hnRNP M. Furthermore, six new derivatives of
BMMP were synthesized, and the patterns of their activities against HIV-1 and cell migration were not uniform, suggesting that the anti-HIV mechanism and the anti-cell migration mechanism of
BMMP are independent. Taken together, the anti-cell migration activity of the anti-HIV
heterocyclic compound BMMP was newly discovered by identification of its
binding protein hnRNP M using a chemical biology approach.